{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Huang CF"],"funding":["Ministry of Education","Kaohsiung Medical University","Ministry of Health and Welfare","Kaohsiung Medical University Hospital"],"pagination":["883-894"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11540343"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(4)"],"pubmed_abstract":["<h4>Background/aims</h4>Steatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations in CHC are associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to elucidate whether hepatitis C virus (HCV) eradication mitigates MASLD occurrence or resolution.<h4>Methods</h4>We enrolled 5,840 CHC patients whose HCV was eradicated by direct-acting antivirals in a nationwide HCV registry. MASLD and the associated cardiometabolic risk factors (CMRFs) were evaluated at baseline and 6 months after HCV cure.<h4>Results</h4>There were 2,147 (36.8%) patients with SLD, and 1,986 (34.0%) of them met the MASLD criteria before treatment. After treatment, HbA1c (6.0% vs. 5.9%, P<0.001) and BMI (24.8 kg/m2 vs. 24.7 kg/m2, P<0.001) d"],"journal":["Clinical and molecular hepatology"],"pubmed_title":["Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan."],"pmcid":["PMC11540343"],"funding_grant_id":["111CM-KMU-07","(KMUHDK(A)113002","KMUH111-1R02","KMUH111-1R05","NSTC 112-2314-B-037-087","KMUH111-1R06","MOHW113-TDU-B-221-124007","NSTC 112-2923-B-037-002-MY3","KMUH-DK(C)111004","NSTC112-2314-B-037-004","KMUH112-2R07","NSTC 112-2314-B-037-009","NYCUKMU-111-I004","KMUH-DK(B)111003~2","KMUH112-2R11","MOST111-2314-B-037-069-MY2","NSTC 112-2314-B-037-076-MY3"],"pubmed_authors":["Tsai PC","Wei YJ","Jang TY","Hsieh MY","Huang CF","Huang CK","Wang CW","Lin YH","Lin TC","Chuang WL","Yu ML","Dai CY","Liang PC","Yeh ML","Huang JF"],"additional_accession":[]},"is_claimable":false,"name":"Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan.","description":"<h4>Background/aims</h4>Steatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations in CHC are associated with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to elucidate whether hepatitis C virus (HCV) eradication mitigates MASLD occurrence or resolution.<h4>Methods</h4>We enrolled 5,840 CHC patients whose HCV was eradicated by direct-acting antivirals in a nationwide HCV registry. MASLD and the associated cardiometabolic risk factors (CMRFs) were evaluated at baseline and 6 months after HCV cure.<h4>Results</h4>There were 2,147 (36.8%) patients with SLD, and 1,986 (34.0%) of them met the MASLD criteria before treatment. After treatment, HbA1c (6.0% vs. 5.9%, P<0.001) and BMI (24.8 kg/m2 vs. 24.7 kg/m2, P<0.001) d","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2025-04-04T02:36:07.159Z","creation":"2025-04-04T02:36:07.159Z"},"accession":"S-EPMC11540343","cross_references":{"pubmed":["39069721"],"doi":["10.3350/cmh.2024.0414"]}}